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Abstract The tissue inhibitors of matrix metalloproteinases
(MMPs), TIMP-1 and TIMP-2, are also angiogenesis inhibi-
tors. Cathepsin B and MMPs are found at sites of neovascular-
ization in pathologies such as cancer and osteoarthritis.
Treatment of TIMP-1, TIMP-2, and of a mixture of both
inhibitors from human articular chondrocytes with cathepsin B
resulted in their fragmentation, whereby they lost their MMP-
inhibitory and anti-angiogenic activities. Our data suggest that,
besides directly participating in tissue destruction, cathepsin B
can be harmful for two further reasons: it raises the activity of
the MMPs also in the absence of mechanisms up-regulating these
enzymes, and it stimulates angiogenesis. This is a prerequisite for
blood vessel invasion in a variety of pathological situations of
which cancer and osteoarthritis are prominent examples.
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1. Introduction
Angiogenesis is a pivotal step in tumor growth and meta-
stasis, and in non-neoplastic situations such as ocular, myo-
cardial, intestinal, reproductive and rheumatic diseases [1].
Neovascularization depends on angiogenic factors and extra-
cellular proteolysis by matrix metalloproteinases (MMPs),
which are regulated by the tissue inhibitors of matrix metal-
loproteinases (TIMPs), a family of proteins consisting so far
of four members, TIMP-1 to TIMP-4 [2]. TIMP-1 and TIMP-
2 are multifunctional proteins, which not only exhibit a broad
speci¢city of inhibition against the MMPs, but also function
as growth factors and as inhibitors of angiogenesis [3]. The
avascularity of articular cartilage and the characteristic resist-
ance of this tissue to invasion by tumors and blood vessels
have been attributed to the presence of anti-angiogenic factors
[4], which are at the same time inhibitors of collagenase [5].
Such factors have been isolated from cartilage [6] and cultured
chondrocytes [7,8], and found to belong to the TIMP family
[2,8]. Cartilage neovascularization is necessary for its miner-
alization and osteophyte formation [9], a complicating feature
in osteoarthritis, the major cause of rheumatic disability in
humans.
Here we show that the cysteine peptidase cathepsin B, an
important mediator of tissue degradation in tumor invasion
[10^13] and osteoarthritis [14,15], inactivates TIMP-1 and
TIMP-2. This suggests a new adverse role for cathepsin B
because it shares with the MMPs the same pathological sites
of action.
2. Materials and methods
2.1. Preparation and assay of crude collagenase from human skin
¢broblast
Normal human skin was processed by standard methods to isolate
¢broblasts. The cells were plated at a density of 5U106 cells in 75 cm2
culture £asks in Dulbecco’s modi¢ed Eagle’s medium (DMEM) sup-
plemented with 10% fetal calf serum, and cultured until they reached
con£uence. Thereafter the medium was removed and the cells washed
with phosphate-bu¡ered saline. Serum-free DMEM containing 10 ng/
ml of human recombinant interleukin-1L was then added. The con-
ditioned media were collected after 48 h, cleared by centrifugation,
and stored frozen at 320‡C in aliquots. Acid-soluble calf skin colla-
gen (Sigma, St. Louis, MO, USA) was acetylated with 14C-acetic
anhydride and collagenase activity determined by a scaled-down var-
iant of the di¡use ¢bril collagenase assay [16].
2.2. Collagenase inhibitory activity from cultured chondrocytes
Chondrocytes were prepared from pooled normal human knee and
femoral head articular cartilage [15]. Primary cells were cultured in a
1:1 mixture of DMEM and Ham’s F-12 media containing 3% fetal
calf serum. These conditions were su⁄cient for preserving the di¡er-
entiated phenotype [15] during the experiment time as monitored by
the secretion of cathepsin B, a marker of the dedi¡erentiated chon-
drocyte [17]. Adherent cells were rinsed twice with serum-free
DMEM/F-12 and further cultured in this medium. After 48 h, the
conditioned media were collected and fresh serum-free medium was
added to the cells. The procedure was repeated twice at 48 h intervals.
The collected media were immediately supplemented with 1 WM of
3,4-dichloroisocoumarin and 1 WM of trans-epoxysuccinyl-L-leucyl-
amido-(4-guanidino)butane (E-64), ¢nal concentrations, to block
serine and cysteine endopeptidase activities. After exhaustive dialysis
against doubly distilled water, the media were lyophilized. These lyo-
philisates were reconstituted in 0.05 M Tris-HCl bu¡er, pH 7.60,
containing 0.2 M NaCl and 1 mM CaCl2, and 100 Wl portions were
applied to a Superdex 75 HR 10/30 gel chromatography column
(Pharmacia, Uppsala, Sweden) equilibrated and run with the same
bu¡er at a £ow rate of 0.5 ml/min in a fast protein liquid chromatog-
raphy apparatus. Fractions of 250 Wl were collected and assayed for
collagenase inhibitory activity as described above. Fractions contain-
ing collagenase inhibitory activity from several runs were pooled,
concentrated and washed against H2O using an ultracentrifugal ¢lter
with a molecular mass cut o¡ 10 kDa. Following 12.5% SDS-PAGE
under both reducing and non-reducing conditions of the concentrated
fractions containing collagenase inhibitory activity, proteins were
transferred to nitrocellulose membranes. Immunoblotting was carried
to reveal human TIMP-1 and TIMP-2. The primary antibodies were
monoclonal mouse anti-human TIMP-1 antibodies and polyclonal
rabbit anti-human TIMP-2 antibodies (NMI, San Diego, CA,
USA). The antibodies to TIMP-1 preferentially recognized the antigen
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under non-reducing conditions, while those to TIMP-2 optimally
bound the antigen under reducing conditions. The enhanced chemilu-
minescence immunoblotting, light emitting, non-radioactive method
(ECL) from Amersham Life Science (Little Chalfont, UK) was used
for detection of the immobilized primary antibodies conjugated with
horseradish peroxidase-labeled secondary antibodies. The antibodies
described above were also used for treating the enriched collagenase
inhibitory fraction from human articular chondrocyte cultures, fol-
lowed by precipitation with protein G-Sepharose (Pharmacia).
2.3. Angiogenesis assays
On day 3 of development, fertilized chick embryos were removed
from their shells, placed in plastic Petri dishes, and maintained in a
humidi¢ed incubator under 5% CO2 at 37‡C. On day 5 of develop-
ment, 6 Wl of the samples to be tested (or the same volume of sterile
water as control) was applied to a sterile Whatman ¢lter (3 mm
diameter) and placed on the surface of the growing chorioallantoic
membrane (CAM). After 48 h exposure of the CAMs to samples, the
¢lters were removed, results evaluated under a binocular microscope
and the images registered digitally. The response was evaluated as
positive or negative depending on the presence or absence of newly
formed small capillaries using 10 eggs for each experiment.
2.4. Degradation of TIMPs by cathepsin B
The mature form of cathepsin B was a⁄nity-puri¢ed from human
kidney [18] and was free of other enzymes as ascertained by electro-
phoresis, speci¢city tests with substrates and inhibitors, and N-termi-
nal sequencing. Cathepsin B (containing the pro-form and the single-
chain form) was also prepared from conditioned media of dedi¡eren-
tiated human articular chondrocytes by gel chromatography [12] fol-
lowed by ion exchange chromatography on DEAE-Sephacel (Pharma-
cia). Human recombinant, non-glycosylated TIMP-1 whose Asn-30
and Asn-78 were mutated to Ala was expressed in CHO K1 cells
and puri¢ed on MacroPrep 50Q anion exchange resin (Bio-Rad),
Green A Dyematrex (Amicon) and Sephacryl S-200 (Pharmacia). Re-
combinant human, glycosylated TIMP-1 was expressed in CHO K1
cells and puri¢ed using anti-(human TIMP-1) a⁄nity chromatography
[19]. Human TIMP-2 was puri¢ed from the medium of uterine cer-
vical ¢broblasts [20]. The incubation solutions in 50 mM sodium
acetate bu¡er, 2 mM dithiothreitol, 2 mM EDTA, pH 5.50, contained
cathepsin B (5 mg/ml ¢nal concentration) and recombinant wild-type
or non-glycosylated TIMP-1 (¢nal concentrations in di¡erent experi-
ments 100^160 Wg/ml), or the same cathepsin B concentration and
TIMP-2 (¢nal concentrations in di¡erent experiments 25^57 mg/ml).
Incubation was performed at 30‡C, reaction was stopped at time
intervals by making the solution 2 mM with iodoacetic acid, and
the progressive disappearance of the original protein band followed
by SDS-PAGE. After 5 h of incubation the original proteins were
completely digested giving a mixture of peptides. Control experiments
included the addition of the cathepsin B-speci¢c inactivator CA-074 at
a ¢nal concentration of 1 mM. MALDI-TOF spectra of TIMP-1 and
TIMP-2 peptides were accumulated using a Voyager Elite instrumen-
tation (PerSeptive Biosystems, Framingham, MA, USA) with K-cya-
no-4-hydroxy-cinnamic-acid (5 mg/ml in 50% acetonitrile and 0.1%
tri£uoroacetic acid in water) as the matrix. Samples were analyzed
in pulsed extraction re£ectron mode using an acceleration voltage of
20 kV, a pulse delay time of 75 ns, a grid voltage of 55% and a guide
voltage of 0.05%. Peptide sequences matching the determined molec-
ular masses were calculated with the software PAWS (Protein Anal-
ysis WorkSheet) of ProteoMetrics (http://www.proteometrics.com).
3. Results
3.1. Enrichment of a collagenase inhibitory fraction from
articular chondrocytes
Conditioned media of primary cultures of human articular
chondrocytes were fractionated by gel chromatography. Frac-
tions showing collagenase inhibitory activity were found in the
molecular mass range 18^30 kDa. After SDS-PAGE under
both non-reducing and reducing conditions of pooled frac-
tions containing collagenase inhibitory activity, immunoblot-
ting with anti-human TIMP-1 and TIMP-2 antibodies re-
vealed the presence of both MMP inhibitors. The anti-
human TIMP-1 antibodies recognized a band with an appar-
ent Mr of about 27 000 under non-reducing conditions (Fig.
1), which corresponds to glycosylated TIMP-1, whereas no
epitopes were recognized after reduction of the antigen. Con-
versely, the anti-human TIMP-2 antibodies reacted with the
partially puri¢ed collagenase inhibitory activity preferentially
under reducing conditions and detected a band at 24 kDa
(Fig. 1). The apparently higher molecular mass of TIMP-2
under reducing conditions (24 kDa) instead of the expected
Table 1
Peptides recovered after complete digestion of human TIMP-1 by human cathepsin B
Mass (D) Matching peptides
5004.2 þ 1.5 T[26^68]S; H[77^120]Y
2919.9 þ 0.9 V[24^47]K
2576.4 þ 1.0 Y[120^143]T; T[128^150]Q
2378.5 þ 0.7 Q[36^55]A
2025.6 þ 0.8 A[51^69]V; L[152^169]R
The peptide molecular masses were determined by MALDI-TOF spectrometry, and peptide fragments matching the masses were calculated
with the PAWS program. The sequence below (amino acids 1^184) represents the whole molecule of human TIMP-1.
1 CTCVPPHPQT AFCNSDLVIR AKFVGTPEVN QTTLYQRYEI KMTKMYKGFQ 50
51 ALGDAADIRF VYTPAMESVC GYFHRSHNRS EEFLIAGKLQ DGLLHITTCS 100
101 FVAPWNSLSL AQRRGFTKTY TVGCEECTVF PCLSIPCKLQ SGTHCLWTDQ 150
151 LLQGSEKGFQ SRHLACLPRE PGLCTWQSLR SQIA 184
Fig. 1. Presence of TIMP-1 and TIMP-2 in the conditioned media
of human articular chondrocytes. Concentrated spent culture me-
dium was chromatographed on Superdex 75 HR, and fractions con-
taining collagenase inhibitory activity in the molecular mass range
18^30 kDa were pooled and concentrated. After 12.5% SDS-PAGE
under reducing (R) and non-reducing (NR) conditions, immunoblot
analysis was carried out with antibodies to TIMP-1 and to TIMP-2.
Numbers and arrows indicate the molecular masses (kDa) of stand-
ards and the TIMP bands, respectively. The bands at Mr higher
than 30 000 were due to non-speci¢c binding of the secondary anti-
body.
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value of 22 kDa under non-reducing conditions has been re-
ported [8].
3.2. Anti-angiogenic properties of TIMP-containing fractions
from articular chondrocytes
To determine if the collagenase inhibitory fraction from
conditioned media of human articular chondrocytes was ca-
pable of inhibiting angiogenesis in vivo, the CAM assay was
used. Fig. 2b shows a signi¢cant inhibition of embryonic neo-
vascularization in the zone underneath the ¢lter. This e¡ect
was observed in all of the eggs tested, while control CAMs
developed vascular zones (Fig. 2a). Inhibition of capillary
formation by human recombinant TIMP-1 and puri¢ed
TIMP-2 was tested under the same conditions. TIMP-1 had
no appreciable e¡ects in inhibiting neovascularization of the
CAM (Fig. 2c) in 80% of the eggs tested, and in 20% of them
a moderate e¡ect was seen. In contrast, TIMP-2 inhibited
angiogenesis in all of the samples tested (Fig. 2d), thus rein-
forcing the concept that it is a major inhibitor of vasculariza-
tion [2]. TIMP-1 and TIMP-2 seem to play di¡erent roles in
angiogenesis. While the primary function of TIMP-1 is inhi-
bition of MMPs used by endothelial cells for tissue invasion
(this property may barely be observable in the CAM assay),
TIMP-2 mainly acts as an inhibitor of endothelial cell prolif-
eration [2]. The collagenase inhibitory fraction from chondro-
cyte conditioned media was separately treated with antibodies
against TIMP-1 and TIMP-2 and then subjected to CAM
assays (not shown). Immunoprecipitation of TIMP-1 com-
pletely abolished the already modest anti-angiogenic activity,
while treatment with antibodies against TIMP-2 inhibited vas-
cularization in 50% of the eggs and weakened the process in
the remaining samples. The lack of total precipitation of
TIMP-2 was due to the fact that the antibodies to this protein
preferentially reacted with reduced TIMP-2. However, this
experiment qualitatively shows that, in the conditioned media
of articular chondrocytes, TIMP-2 was a species able to in-
hibit angiogenesis.
3.3. Inactivation of TIMPs by cathepsin B
Upon incubation of human TIMP-1 and TIMP-2 with hu-
man kidney cathepsin B the two inhibitors were degraded with
extensive fragmentation in a time-dependent manner. Both
non-glycosylated and wild-type recombinant human TIMP-1
were equally susceptible to proteolysis by cathepsin B. The
reaction products were analyzed by MALDI-TOF. The frag-
Fig. 2. Anti-angiogenic activity demonstrated with the CAM assay.
The dashed circles (3 mm diameter) show the area where a sterile
Whatman ¢lter, impregnated with 6 Wl of sample, was placed on the
¢fth day of development of a fertilized chick embryo. The ¢lter was
removed after 48 h for evaluation. a: Control with water. b: Colla-
genase inhibitory fraction from the spent culture medium of human
articular chondrocytes. c: 5.2 Wg of human recombinant TIMP-1. d:
0.7 Wg of human puri¢ed TIMP-2 (the fuzzy visible capillaries repre-
sent microvessels which are out of focus and belong to another,
deeper level). e : Fractionated collagenase inhibitory activity from
the spent medium of articular chondrocytes after incubation with
cathepsin B. f: 0.7 Wg of cathepsin B-treated human puri¢ed TIMP-
2. Capillary growth is visible in panels a, c, e, and f, but not so in
panels b and d.
Table 2
Peptides recovered after complete digestion of human TIMP-2 by human cathepsin B
Mass (D) Matching peptides
6957.0 þ 0.7 S[75^136]I; D[77^138]C
4355.9 þ 1.0 C[128^164]F
4039.6 þ 1.2 G[37^71]V
3531.7 þ 1.0 T[110^139]Y; S[111^140]I; T[112^141]S
2717.6 þ 0.8 E[127^149]M
2714.3 þ 0.9 S[111^133]C; I[157^180]G
2658.4 þ 0.8 L[118^139]Y; N[119^140]I
2133.7 þ 0.6 S[25^43]I
1629.4 þ 0.5 W[148^160]H
1581.5 þ 0.5 I[50^62]F; M[124^137]P
798.5 þ 0.3 Q[123^129]K
758.9 þ 0.3 L[85^92]G
757.0 þ 0.3 G[92^98]I
The peptide molecular masses were determined by MALDI-TOF spectrometry, and peptide fragments matching the masses were calculated
with the PAWS program. The sequence below (amino acids 1^194) represents the whole molecule of human TIMP-2.
1 CSCSPVHPQQ AFCNADVVIR AKAVSEKEVD SGNDIYGNPI KRIQYEIKQI 50
51 KMFKGPEKDI EFIYTAPSSA VCGVSLDVGG KKEYLIAGKA EGDGKMHITL 100
101 CDFIVPWDTL STTQKKSLNH RYQMGCECKI TRCPMIPCYI SSPDECLWMD 150
151 WVTEKNINGH QAKFFACIKR SDGSCAWYRG AAPPKQEFLD IEDP 194
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ments derived from TIMP-1 and TIMP-2 and their molecular
masses are shown in Tables 1 and 2, respectively. Two of the
peptides produced by cathepsin B cleavage of TIMP-1, V[24^
47]K and Q[36^55]A, could unequivocally be assigned, while
three other fragments each matched two peptides with masses
within the experimental error. Among these, and to mention
the N-terminal cleavage sites only, peptide L[152^169]R can
be generated by hydrolysis between two Leu residues, a cleav-
age motif known from cathepsin B degradation of thyroglo-
bulin [21]. Peptide T[26^68]S is generated by cleavage after a
Val-Gly sequence, representing the subsites P2-P1 [22], respec-
tively, a motif that is also known from thyroglobulin cleavage
by cathepsin B [21]. Peptide A[51^69]V derives from cleavage
between residues 50 and 51, having Gln at P1 and Leu at P2P,
a major site of cathepsin B cleavage in the insulin B-chain
[23]. Also hydrolysis between Ser and His (peptide H[77^
120]Y) has been recorded as a major site of cleavage in the
insulin B-chain [23]. TIMP-2 digestion resulted in more exten-
sive fragmentation, with eight clearly de¢ned peptides and ¢ve
more peaks matching di¡erent peptides. For many of these,
cleavage sites corresponded to known P1-speci¢cities of ca-
thepsin B, such as Leu (peptides D[77^138]C, S[111^140]C,
N[119^140]I, S[111^133]C), Ser (peptides T[112^141]S,
L[118^139]Y), and Gln (peptides I[50^62]F, M[124^137]P)
[21,23]. CA-074, a cathepsin B-speci¢c inactivator [24], totally
prevented degradation of both TIMP-1 and TIMP-2, indicat-
ing that their cleavage was only due to cathepsin B and not to
other endopeptidases possibly present as contaminants. Pro-
teolysis by cathepsin B is generally complex as a result of the
combined endo- and exoproteolytic activities of the enzyme
[25]. Due to this property, cathepsin B cleaves the cartilage
proteoglycan, aggrecan, producing a fragment terminating in
the sequence VDIPEN, that was previously considered an ex-
clusive feature of the MMPs [26].
After incubation of both TIMPs and of the partially puri-
¢ed collagenase inhibitory activity from conditioned media of
human articular chondrocytes with human kidney cathepsin
B, their ability to inhibit MMPs was completely lost. The
same result was obtained using a cathepsin B preparation
from conditioned media of dedi¡erentiated human articular
chondrocytes. CAM assays were performed with TIMP-1,
TIMP-2 and with enriched conditioned medium from chon-
drocyte cultures containing both TIMPs after treatment with
either human kidney cathepsin B or cathepsin B prepared
from conditioned media of dedi¡erentiated human articular
chondrocytes. In all cases, the anti-angiogenic activity of the
samples was completely lost. The e¡ect of this treatment on
the chondrocytic anti-angiogenic activity and TIMP-2 with
chondrocyte cathepsin B is shown in Fig. 2e,f, respectively.
The undisturbed growth of capillaries in the area underneath
the ¢lter con¢rms that none of the peptides generated by
cathepsin B digestion of TIMP-1 and TIMP-2 retained the
anti-angiogenic properties of the corresponding intact mole-
cules. If CA-074 was added to the incubation solutions of
both cathepsin B preparations with TIMPs, their anti-angio-
genic potential was fully retained. Cathepsin B alone had no
in£uence on capillary growth in the CAM assay.
4. Discussion
Destruction of important antagonists of neovascularization
may have a direct impact in conditions characterized by the
concomitant presence of MMPs and cathepsin B in the patho-
logical scenario. Two representative examples are tumor
growth and invasion [10^13,27,28] and osteoarthritis
[14,15,29]. Cathepsin B has been localized in microvascular
endothelial cells around human glioblastoma and prostate
carcinomas, a feature which may play a role in the malignancy
of these tumors [28].
Neovascularization is required for the initiation of cartilage
mineralization [9]. The process of endochondral ossi¢cation
during the growth of osteophytes is characterized by an initial
invasion of cartilage by vascular connective tissue, followed
by osteoclastic resorption. Erosion on one side and formation
of cartilage on the other result in the outgrowth of marginal
osteophytes [30]. In normal articular cartilage, angiogenesis
factors are balanced in their action by vascularization inhib-
itors, with the result that cartilage is e⁄ciently protected from
invasion by capillaries. This balance is obviously disturbed in
osteoarthritic cartilage, as shown histologically by the inva-
sion of new capillaries penetrating the subchondral plate and
the deeper zones of cartilage. We demonstrated active cathep-
sin B at sites of remodeling in osteoarthritic cartilage and in
osteophytes of human osteoarthritic joints [14,15]. The high
levels of interstitial collagenase at sites of vascular invasion, as
well as in the osteoblasts and some osteoclasts of human
osteophytic bone, together with the low levels of TIMP-1 in
the same zones [31], immediately provide a rationale for our
present results: cathepsin B would be responsible for shifting
the balance between MMPs and TIMPs through inactivation
of the latter components. Membrane type 1 MMP acts as a
pericellular ¢brinolysin during the neovascularization process
[32]. This enzyme is not inhibited by TIMP-1, but is regulated
by TIMP-2 and TIMP-3 [33]. Thus, TIMP-2 inactivation by
cathepsin B favors the action of this enzyme also.
The importance of our present results goes beyond cartilage
angiogenesis. They provide a rationale for the presence and
role of cathepsin B in many pathological situations pointing
to novel, deleterious roles of this aggressive enzyme. Besides a
direct participation in tissue destruction, cathepsin B enhances
the activity of the MMPs by destroying their inhibitors, even
in the absence of mechanisms capable of MMP upregulation,
and at the same time behaves as an angiogenesis-stimulating
factor. Indeed, cathepsin B secreted by dedi¡erentiated artic-
ular chondrocytes [17] is the same species produced by inva-
sive tumors [12], and corresponds to the proenzyme, which
undergoes extracellular activation [25].
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